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Available online 19 July 2017Acutemyeloid leukemia (AML) is a severe and often fatal systemicmalignancy. Malignant cells are capable of es-
caping host immune surveillance by inactivating cytotoxic lymphoid cells. In this work we discovered a funda-
mental molecular pathway, which includes ligand-dependent activation of ectopically expressed latrophilin 1
and possibly other G-protein coupled receptors leading to increased translation and exocytosis of the immune
receptor Tim-3 and its ligand galectin-9. This occurs in a protein kinase C and mTOR (mammalian target of
rapamycin)-dependent manner. Tim-3 participates in galectin-9 secretion and is also released in a free soluble
form. Galectin-9 impairs the anti-cancer activity of cytotoxic lymphoid cells including natural killer (NK) cells.
Soluble Tim-3 prevents secretion of interleukin-2 (IL-2) required for the activation of cytotoxic lymphoid cells.
These results were validated in ex vivo experiments using primary samples from AML patients. This pathway
provides reliable targets for both highly speciﬁc diagnosis and immune therapy of AML.yov),
asler@insel.ch (E. Fa







Acutemyeloid leukemia (AML) is a blood/bonemarrow cancer orig-
inating from self-renewing malignant immature myeloid precursors,
which rapidly becomes a systemic malignancy. It is often a fatal disease
becausemalignant cells are capable of suppressing anti-cancer immuni-
ty by impairing the functional activity of natural killer (NK) cells and cy-
totoxic T cells (Golden-Mason et al., 2013;Wang et al., 2007; Khaznadar
et al., 2014). Recent evidence clearly demonstrated an involvement of
the T cell immunoglobulin and mucin domain 3 (Tim-3) - galectin-9
pathway in this immune escape mechanism (Golden-Mason et al.,
2013; Kikushige et al., 2015; Gonçalves Silva et al., 2016). Galectin-9 is
a β-galactoside-binding lectin, which has a tandem structure andsler-Kan),
der the CC BY-Ncontains two carbohydrate recognition domains (CRDs) fused together
by a peptide (Delacour et al., 2009). Galectin-9 has a speciﬁc receptor
on AML cells known as Tim-3 which also could act as its possible traf-
ﬁcker (galectin-9 as all other galectins lacks a signal sequence required
for transport into the endoplasmic reticulum (ER) and thus requires a
trafﬁcking protein for its secretion (Hughes, 1999; Delacour et al.,
2009)). However, the mechanisms underlying the activation of biosyn-
thesis of the components of the Tim-3-galectin-9 autocrine loop,
galectin-9 secretion and its effects on cytotoxic lymphocytes (NK cells
and T cells) remain poorly understood.
Recently, we discovered that humanAML cells – but not healthy leu-
kocytes – express physiologically active latrophilin 1 (LPHN1;
Sumbayev et al., 2016). LPHN1, an adhesion G-protein-coupled recep-
tor, is highly expressed in neuronal axon terminals and in many secre-
tory cells (Davletov et al., 1998; Silva and Ushkaryov, 2010). In all cells
expressing this receptor, LPHN1 activation by its most potent agonist,
α-latrotoxin (LTX) from black widow spider venom (Ushkaryov,
2002), triggers intracellular Ca2+ signaling and exocytosis of neuro-
transmitters and hormones (Volynski et al., 2003). Similarly, ligand-C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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kines and growth factors (Sumbayev et al., 2016). Production of
LPHN1 in AML cells is controlled by themammalian target of rapamycin
(mTOR) (Sumbayev et al., 2016), a highly conserved serine/threonine
kinase that acts as a central regulator of growth and metabolism in
healthy and malignant human myeloid cells (Yasinska et al., 2014). To
function in cell-cell interactions and cell signaling, LPHN1 can interact
with at least two endogenous ligands, Lasso/teneurin-2 (Silva et al.,
2011) and ﬁbronectin leucine rich transmembrane protein 3 (FLRT3)
(Boucard et al., 2014), although only FLRT3 seems to be expressed in pe-
ripheral tissues. In addition to triggering exocytosis by increasing cyto-
solic Ca2+, LPHN1 can enhance the sensitivity of the release machinery
by activating protein kinase C (Liu et al., 2005), which is also thought to
be involved in galectin-9 secretion (Chabot et al., 2002). Based on these
observations, we hypothesized that activation of LPHN1 by its ligands
can induce secretion of galectin-9, thus protecting AML cells against
NK and cytotoxic T cells. This hypothesis has been studied experimen-
tally in the present study.
Here we report that the Tim-3-galectin-9 autocrine loop is
activated in AML cells through protein kinase C (PKC)/mTOR
pathways. These pathways trigger translation of both Tim-3 and
galectin-9 and induce high levels of galectin-9 secretion as well as
the release of soluble Tim-3. Importantly, this effect was also veriﬁed
in the AML patients studied. Galectin-9 was found to impair AML cell
killing by primary human NK cells. Soluble Tim-3 reduced the ability
of T cells to secrete IL-2, a cytokine, which is required for the
activation of both NK cells and cytotoxic T cells (Dhupkar and
Gordon, 2017). Blood plasmas of AML patients contained
signiﬁcantly lower amounts of IL-2 compared to those of healthy
donors. We conﬁrmed that PKC activation occurred in AML cells in
a LPHN1-dependent manner. The LPHN1 agonist LTX and natural
ligand FLRT3 upregulated the Tim-3-galectin-9 autocrine loop in a
PKC-dependent manner. Based on our ﬁndings, we conclude that
LPHN1/PKC/mTOR/Tim-3-galectin-9 is a biosynthetic and secretory
pathway which is operated by human AML cells resulting in a
decrease of immune surveillance and promotion of disease
progression.2. Materials and Methods
2.1. Materials
RPMI-1640 medium, fetal bovine serum and supplements and basic
laboratory chemicals were purchased from Sigma (Suffolk, UK).
Maxisorp™microtitre plates were provided either by Nunc (Roskilde,
Denmark) and Oxley Hughes Ltd. (London, UK). Mousemonoclonal an-
tibodies directed against mTOR and β-actin, as well as rabbit polyclonal
antibodies against phospho-S2448 mTOR, galectin-9, HRP-labelled rab-
bit anti-mouse secondary antibody were purchased from Abcam (Cam-
bridge, UK). Mouse monoclonal antibody against FLRT3 was obtained
from Santa Cruz Biotechnology (Heidelberg, Germany). The polyclonal
rabbit anti-peptide antibody (PAL1) against LPHN1 was described pre-
viously (Davydov et al., 2009). LTXwas puriﬁed as previously described
(Ashton et al., 2000). Goat anti-mouse and goat anti-rabbit ﬂuorescence
dye-labelled antibodies were obtained from LI-COR (Lincoln, Nebraska
USA). ELISA-based assay kits for the detection of galectin-9, Tim-3 and
IL-2 were purchased from Bio-Techne (R&D Systems, Abingdon, UK).
Anti-Tim-3 mouse monoclonal antibody, its single chain variant as
well as human Ig-like V-type domain of Tim-3 (amino acid residues
22–124), expressed and puriﬁed from E. coli (Prokhorov et al., 2015)
were used in our work. Secondary antibodies for confocal laser
microscopy and imaging ﬂow cytometry (goat anti-mouse and goat
anti-rabbit Alexa 488, Alexa 555 and Alexa 647) were from Invitrogen
(Carlsbad, USA). All other chemicals purchased were of the highest
grade of purity.2.2. Cell Lines and Primary Human Cells
THP-1 humanmyeloid leukemiamonocytes, K562 chronicmyeloge-
nous leukemia cells and Jurkat T cells were obtained from the European
Collection of Cell Cultures (Salisbury, UK). Renal clear cell carcinoma
RCC-FG1 cells were obtained from CLS Cell Lines Service (Eppelheim,
Germany). Cells were cultured in RPMI 1640 media supplemented
with 10% fetal bovine serum, penicillin (50 IU/ml) and streptomycin
sulfate (50 μg/ml). LAD2 mast cells were kindly provided by A.
Kirshenbaum and D. Metcalfe (NIH, USA). Cells were cultured in Stem-
Pro-34 serum-free media in the presence of 100 ng/ml SCF
(Kirshenbaum et al., 2003).
Primary human AMLmononuclear blasts (AML-PB001F, newly diag-
nosed/untreated)were purchased fromAllCells (Alameda, CA, USA) and
handled in accordance with the manufacturer's instructions. Primary
human NK cells were puriﬁed from buffy coat blood (prepared from
healthy donors) obtained from the National Health Blood and Transfu-
sion Service (NHSBT, UK) following ethical approval (REC reference:
16-SS-033). Primary CD34-positive HSCs were obtained from Lonza
(Basel, Switzerland).
Femur bones of six-week-old C57 BL16mice (25± 2.5 g, kindly pro-
vided by Dr. Gurprit Lall, School of Pharmacy, University of Kent) were
used for the experiments following approval by the Institutional Animal
Welfare and Ethics Review Body. Animals were handled by authorized
personnel in accordance with the Declaration of Helsinki protocols.
Bone marrow was isolated from femur bone heads as described before
(Swamydas and Lionakis, 2013) and whole extracts (1 mg protein/ml)
were then obtained.2.3. Primary Human Plasma Samples
Blood plasma of healthy donors was obtained from buffy coat
blood (originated from healthy donors undergoing routine blood
donation) which was purchased from the National Health Blood
and Transfusion Service (NHSBT, UK) following ethical approval
(REC reference: 16-SS-033). Primary human AML plasma samples
were obtained from the sample bank of University Medical Centre
Hamburg-Eppendorf (Ethik-Kommission der Ärztekammer
Hamburg, reference: PV3469).2.4. Western Blot Analysis
Tim-3, galectin-9, FLRT3, LPHN1 and Gαq were analyzed by
Western blot and compared to β-actin in order to verify equal pro-
tein loading, as previously described (Yasinska et al., 2014). Brieﬂy,
cells were lysed using lysis buffer (50 mM Tris–HCl, 5 mM EDTA,
150 mM NaCl, 0.5% Nonidet-40, 1 mM PMSF, pH 8.0). After centrifu-
gation, the protein content in the supernatants was analyzed. Finally,
samples were added to the same volume of 2× sample buffer
(125 mM Tris–HCl, 2% sodium dodecyl sulfate (SDS), 10% glycerine,
1 mM dithiothreitol (DTT), 0.002% bromophenol blue, pH 6.9) and
boiled for 5 min. Proteins were resolved using SDS–polyacrylamide
gels followed by blotting onto nitrocellulose membranes. Molecular
weights were calibrated in proportion to the running distance of
rainbow markers. For all primary antibodies (see Materials section)
a 1:1000 dilution was used, except those against LPHN1 and FLRT3
(where a 1:500 dilution was used). β-actin staining was used to
conﬁrm equal protein loading as described previously (Yasinska et
al., 2014). LI-COR goat secondary antibodies (dilution 1:2000),
conjugated with ﬂuorescent dyes, were used in accordance with
manufacturer's protocol to visualize target proteins (using a LI-COR
Odyssey imaging system). Western blot data were quantitatively
analyzed using Odyssey software and values were subsequently
normalized against those of β-actin.
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Secreted Tim-3 and galectin-9 were characterized in the RPMI-1640
mediumused to culture THP-1 cells. The proteinswere ﬁrst precipitated
onMaxisorp ELISA plates (seeMaterials section). For this purpose ELISA
plateswere coated overnight using single-chain antibody against Tim-3.
Plates were then blocked with 2% BSA. Tissue culture mediumwas then
applied and incubated for 4 h at room temperature, followed by exten-
sivewashingwith TBST buffer. Proteinswere then extracted using 0.2M
glycine-HCl buffer (pH 2.0). Extracts were neutralized using lysis buffer
and subjected toWestern blot analysis usingmouse anti-Tim-3 and rab-
bit anti-galectin-9 antibodies as described before (Gonçalves Silva et al.,
2016) and above.
2.6. Enzyme-linked Immunosorbent Assays (ELISAs)
Galectin-9, sTim-3 and IL-2 were measured by ELISA using R&D Sys-
tems kits according to manufacturer's protocols. In all cases the proce-
dure involves speciﬁc detection of captured target proteins using
biotinylated detection antibody. The interaction was then analyzed
using streptavidin conjugated with horseradish peroxidase (HRP) ac-
cording to the manufacturer's protocol. Tim-3-galectin-9 complex was
also analyzed by ELISA. Single-chain antibody (described above, dilution
1:100)was used to capture the complex and biotinylated goat R&D Sys-
tems antibody against galectin-9 (detection antibody) was used to de-
tect galectin-9 bound to Tim-3. HRP-labelled streptavidin was then
used to perform quantitative analysis according to the R&D Systems
protocol for the galectin-9 assay kit. Phosphorylation of mTORwas ana-
lyzed by ELISA as previously described (Yasinska et al., 2014).
2.7. In Cell Assays and in Cell Westerns
Weemployed a standard LI-COR in-cellWestern (ICW) assay (meth-
anol was used as permiabilization agent) to analyze total Tim-3 and
galectin-9 expressions in the studied cells. The in-cell (ICA, also called
on-cell) assay was employed to characterize Tim-3 and galectin-9 sur-
face presence in the studied cells. We also used this assay to visualize
binding of LAD2 cells toNK cells. IgE-sensitized LAD2 cellswere exposed
for 5 min to 1 μg/ml, carefully washed with sterile PBS and exposed to
LI-COR goat anti-mouse labelled secondary antibody. Following wash-
ing with PBS, cells were scanned using a LI-COR Odyssey imaging sys-
tem (Gonçalves Silva et al., 2016).
2.8. Confocal Microscopy and Imaging Flow Cytometry
THP-1 cells were grown on 12 mm cover glasses in 24-well plates.
Cells were treated (o/n) with PMA and then ﬁxed/permeabilized for
20 min with ice-cold MeOH or MeOH/acetone. Alternatively cells were
ﬁxed in a freshly prepared 2% paraformaldehyde, washed 3 times with
PBS and then permeabilized with 0.1%TX-100. Cover glasses were
blocked for 1 h at RTwith 10% goat serum in PBS. 1 μg/ml anti-Tim-3 an-
tibody and anti-galectin-9 antibody were used as primary antibodies
and incubated o/n at 4 °C. Goat-anti-mouse Alexa Fluor 488 and goat-
anti-rabbit Alexa Fluor 555 were used as secondary antibodies. Cells
were incubated with secondary antibodies for 45 min at RT. The prepa-
rations were examined on Olympus laser scanning confocal microscope
as described (Prokhorov et al., 2015; Fasler-Kan et al., 2010). Images
were collected and analyzed using proprietary image acquisition soft-
ware. Imaging ﬂow cytometry was performed in accordancewith a pre-
viously described protocol (Fasler-Kan et al., 2016). Brieﬂy,
permiabilized cells were stained with mouse anti-Tim-3 and rabbit
anti-galectin-9 antibodies for 1 h at room temperature. Goat anti-
mouse Alexa Fluor 647 and goat-anti-rabbit Alexa Fluor 488 were
used as secondary antibodies. Images were collected and analyzed
using IDEAS analytical software on ImageStream X mark II (Amnis-
EMD-Millipore, USA).2.9. Synchrotron Radiation Circular Dichroism Spectroscopy
Human recombinant Tim-3, human recombinant galectin-9 and
Tim-3-galectin-9 complex were analyzed using SRCD spectroscopy at
beam line 23, Diamond Light Source (Didcot, UK). SRCD measurements
were performed using 0.2 μg/ml of samples in 10 cm path length cell,
3 mm aperture diameter and 800 μl capacity using Module B with
1 nm increment, 1 s integration time, 1.2 nm bandwidth at 23 °C
(Hussain et al., 2012a, 2012b; Siligardi and Hussain, 2015). The results
obtained were processed using CDApps (Hussain et al., 2015) and
OriginLab™.
2.10. PKCα Activity Assay
The catalytic activity of PKCα was measured as described before
based on its ability to phosphorylate speciﬁc substrate in a reaction buff-
er containing 20mMTris-HCl (pH 7.5), 20 μMATP, 5mMMgCl2 and 200
μM CaCl2 (Micol et al., 1999). Phosphate groups attached to the sub-
strate were detected using colorimetric assay (Abooali et al., 2014).
2.11. Cell Viability Assay
Cell viability was analyzed using the Promega UK Ltd. (Southamp-
ton, UK) assay kit. We used an MTS colorimetric assay for assessing
cell metabolic activity. NAD(P)H-dependent cellular oxidoreductase en-
zymes playing crucial role in human myeloid cell survival (Sumbayev
and Nicholas, 2010), reﬂect the number of viable cells present. Cells
were incubated with 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)
and then absorbance was measured at 490 nm in accordance with the
manufacturer's protocol.
2.12. Leukemia Cell Protection Assay
K562 and NK cells were cultured separately or as a 1:2 co-culture
(K562:NK) for 16 h, at 37 °C, in the absence or presence of 0.5–
5 ng/ml of galectin-9. The unﬁxed cell cultures were then imaged
under an inverted microscope (TE200, Nikon), using phase-contrast
lighting, a digital camera and the WinFluor image acquisition software
(J. Dempster, University of Strathclyde). Raw images were analyzed
using the ImageJ software (Schindelin et al., 2015), including illumina-
tion correction, background subtraction, overlapping cells separation,
edge artefacts elimination, and particle size optimization (based on
the size difference between K562 and NK cells). The selected areas
were then applied to the raw images for automatic cell counting.
2.13. Statistical Analysis
Each experiment was performed at least three times and statistical
analysis when comparing two events at a time was conducted using a
two-tailed Student's t-test. Multiple comparisons were performed
using ANOVA test. Post-hoc Bonferroni correction was applied. Statisti-
cal probabilities (p) were expressed as * where p b 0.05; **, p b 0.01 and
*** when p b 0.001.
3. Results
3.1. Differential Proteolytic Enzymes are Involved in the Secretion of the
Tim-3 and Galectin-9 Complex in Human AML Cells
We investigated differential proteolytic shedding of free and
galectin-9-bound Tim-3 from the surface of human AML cells as a pos-
sible mechanism for the secretion of these proteins. Firstly, we exam-
ined the medium used to culture THP-1 human AML cells with or
without 16 h exposure to 100 nM phorbol 12-myristate 13-acetate
(PMA) known to activate proteolytic shedding of Tim-3 (Moller-
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medium and extracted the precipitate as outlined in the Materials and
Methods. Extracts were subjected to Western blot analysis followed
by speciﬁc detection of galectin-9 and Tim-3. Speciﬁc galectin-9 bands
appeared at around 32 kDa (molecular weight of galectin-9) as well as
52 kDa (Fig. 1A). Interestingly, the 52 kDa band was also detectable by
anti-Tim-3 antibody (Fig. 1A), suggesting that this band corresponds
to the unbroken Tim-3-galectin-9 complex. Furthermore, speciﬁc Tim-
3 bands appeared at around 33 kDa (molecular weight of soluble Tim-
3 – sTim-3) and around 20 kDa. This 20 kDa band is likely to be a
fragment of Tim-3 shed together with galectin-9 being released from
the complex during theWestern blot procedure (Fig. 1A). This suggests
that the Tim-3 protein fragment complexed with galectin-9 might be
shed at different cleavage site(s). Interestingly, the amount of all the
proteins detected was clearly higher in PMA-treated samples.
It has recently been found that Tim-3 can be shed from the cell sur-
face by a disintegrin andmetalloproteinase domain-containing proteins
(ADAM) 10/17 (Moller-Hackbarth et al., 2013). We therefore investi-
gated whether these proteases are associated with release of free Tim-
3 and/or of the galectin-9-Tim-3 complex. We exposed THP-1 cells for
16 h to 100 nM PMA, after which the PMA-containing medium was re-
moved and replaced with the same medium containing 100 μM
GI254023X (ADAM 10 and 17 inhibitor) or 100 μMBB-94, a matrix me-
talloproteinase inhibitor. The cells were incubated for 4 h and levels of
Tim-3 and galectin-9 were then measured in the culture medium by
ELISA. We also measured soluble Tim-3-galectin-9 complex by captur-
ing Tim-3 using a single-chain antibody and then detecting galectin-9
using a biotinylated anti-galectin-9 antibody. We found that PMAFig. 1. Free and galectin-9-bound Tim-3 is shed differentially from the cell surface. THP-1 cells
medium and cells exposed to the indicated concentrations of GI254023X (ADAM10/17 inh
incubated for 16 h after which medium was changed and cells incubated for further 4 h and u
fragment (Tim-3 (fr)) and 33 kDa (sTim-3)) was performed in medium collected after ﬁnal 4
and Methods (A). All the samples were subjected to ELISA-based detection of galectin-9
representative of six which gave similar results. Quantitative data represent mean values ± SEtreatment signiﬁcantly upregulated sTim-3 release as well as the release
of galectin-9 (a similar increase was observed in the Tim-3-galectin-9
complex, Fig. 1B). GI254023X and BB-94 decreased PMA-induced sTim-
3 release but did not affect the release of either galectin-9 or the Tim-3-
galectin-9 complex (Fig. 1B), suggesting that this complex is differentially
shed from the cell surface.
3.2. Protein Kinase C is Involved in the Activation of Tim-3 and Galectin-9
co-secretion by AML Cells
We considered the levels of Tim-3 and galectin-9 remaining in
THP-1 cells following 16 h of exposure to speciﬁc PKC activator
PMA. It was found that, despite the levels of released sTim-3,
galectin-9 and Tim-3-galectin-9 complex were increased in PMA-
treated cells, the levels of respective cell-associated proteins
decreased (Fig. 2). Interestingly, a speciﬁc band in the range of
70 kDa detectable by both anti-Tim-3 and anti-galectin-9 antibodies
was present in all the assays (Fig. 2). This molecular weight
corresponds to a sum of those of uncleaved Tim-3 and galectin-9.
This indicates that a complex between full Tim-3 and galectin-9 is
ﬁrst formed before undergoing shedding, which results in a release
of its soluble form corresponding to the 52 kDa species, as described
above. Our observations were conﬁrmed by co-localization assays
using confocal microscopy (Fig. 3). Following 24 h exposure to
100 nM PMA, paraformaldehyde-ﬁxed non-permeabilized and
methanol-permeabilized THP-1 human AML cells were investigated.
We found that both galectin-9 and Tim-3 were present on the cell
surface. In permeabilized cells there was clear evidence of co-localizationwere exposed for 16 h to 100 nM PMA; medium was then exchanged for fresh PMA-free
ibitor) and BB-94 (matrix metalloproteinase inhibitor). Non treated THP-1 cells were
sed as a control. Western blot characterization of galectin-9 and Tim-3 variants (20 kDa
h of incubation of resting and PMA-pre-treated THP-1 cells as outlined in the Materials
, soluble Tim-3 and Tim-3-galectin-9 complex (B). Images are from one experiment
M of six independent experiments; *p b 0.05; **p b 0.01 vs. control.
Fig. 2.PMAactivates Tim-3 andgalectin-9production and release aswell as generation of Tim-3-galectin-9 complex. THP-1 cellswere treatedwith 100nMPMA for 16 h.Non-treated THP-
1 cells were used as a control. Cells were then harvested and galectin-9 as well as Tim-3 were analyzed in whole cell extracts by Western blot. Both proteins and Tim-3-galectin-9
complexes were analyzed by ELISA in the medium used to treat the cells. The bar diagram on the top shows the comparative analysis (expressed in % control) of galectin-9 and Tim-3-
galectin-9 complex levels released by non-treated and PMA-treated THP-1 cells. Images are from one experiment representative of three which gave similar results. Quantitative data
are the mean values ± SEM of three independent experiments; *p b 0.05; **p b 0.01; ***p b 0.001 vs. control.
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cytometry (Supplementary Fig. 1). In non-permeabilized cells we saw
sectors full of either Tim-3 or galectin-9, without substantial co-localiza-
tion. Given that galectin-9 is soluble, it can remain on the cell surface
only if it is bound to its receptor, Tim-3 (Fig. 3). Taken together our
ﬁndings suggest that Tim-3 is either externalized on its own or acts as a
trafﬁcker for galectin-9 (which lacks the signal domain required for
secretion and thus requires a trafﬁcker). Given that PMA, a speciﬁc PKC
activator, signiﬁcantly increases Tim-3 and galectin-9 secretion, it is likely
that PKC is involved in the Tim-3 and galectin-9 co-secretion process.Fig. 3. Co-localization of Tim-3 and galectin-9 in PMA-activated THP-1 cells. Co-localization of
following 24 h of exposure to 100 nM PMA using confocal microscopy (see Materials and M
similar results.3.3. Levels of Soluble Tim-3 andGalectin-9 are Highly Increased in the Blood
Plasma of AML Patients: Characterization of the Tim-3-galectin-9 Complex
in Human Blood Plasma
We then sought to conﬁrmourﬁndings in primary samples collected
from AML patients. We analyzed plasma samples from 98 AML patients
versus healthy donors and found that galectin-9 and Tim-3 levels were
strikingly increased in blood plasma of AMLpatients (Fig. 4A, B, E and F).
Five randomly selected plasma samples from the group of studied AML
patients and ﬁve from healthy donors were then subjected to detectionTim-3 and galectin-9 was analyzed in non-permeabilized and permeabilized THP-1 cells
ethods for details). Images are from one experiment representative of six which gave
Fig. 4. Levels of galectin-9 and soluble Tim-3 are highly increased in blood plasma of AML patients. Galectin-9 and Tim-3 were measured by ELISA in blood plasma obtained from healthy
donors and AML patients (A, B, E and F). The levels of Tim-3-galectin-9 complexweremeasured by ELISA in blood plasma of ﬁve randomly picked healthy donors and AML patients (C and
G). Tim-3 and galectin-9were characterized byWestern blot in blood plasma fromﬁve randomly chosen AML patients (D). Correlations between Tim-3 and galectin-9 aswell as between
galectin-9 andTim-3-galectin-9 complexwas then determined (H, I, J and K). Images are fromone experiment representative ofﬁvewhich gave similar results. Quantitativedata represent
mean values ± SEM of three independent experiments; *p b 0.05; **p b 0.01; ***p b 0.001 vs. control.
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increase in Tim-3-galectin-9 complex in AML samples was similar to
that of galectin-9 (Fig. 4C and G). We then randomly chose ﬁve plasma
samples from the group of studied AML patients and analyzed Tim-3
and galectin-9 levels by Western blot (Fig. 4D). Prior to loading onto
the SDS-PAGE, samples were sonicated and boiled for 5 min at 95 °C.
We found that sTim-3 and galectin-9 were clearly detectable. We
could also see a clear band (probably representing the soluble form of
the Tim-3-galectin-9 complex) at around 52 kDa (detectable by both
anti-Tim-3 and anti-galectin-9 antibodies). This suggests that the com-
plex released by THP-1 cells (Fig. 1) and the one found in blood plasma
is unlikely to be formed after secretion. If this had been the case, its mo-
lecular weight would have been around 65 kDa (33 kDa for sTim-3 and
32 kDa for galectin-9) rather than 52 kDa. A speciﬁc band was also de-
tectable at around 20 kDa (Fig. 4D). These results are in line with
those obtained for soluble forms of Tim-3, galectin-9 and Tim-3-
galectin-9 complex released by THP-1 cells conﬁrming that sTim-3
and Tim-3 complexed with galectin-9 are likely to be differentially
shed from plasma membranes of AML cells. Interestingly, there is a
clear evidence of a correlation between Tim-3 and galectin-9 levels in
the plasma of both healthy donors and AML patients and these correla-
tion levels were very similar to each other (Fig. 4H and I) suggesting a
co-release of both proteins in both cohorts.
3.4. Tim-3 Binding Alters the Conformation of Galectin-9
In order to assess the biophysical properties of Tim-3, galectin-9 and
the Tim-3-galectin-9 complex we investigated them using synchrotron
radiation circular dichroism (SRCD) spectroscopy at Diamond Light
Source (Beam Line 23, Supplementary Fig. 2). Structural organization
of Tim-3 and galectin-9 as well as their interaction are schematically
presented in the Fig. 5A. Galectin-9 interacts with non-glycosylated
Tim-3 with nanomolar afﬁnity (Kd = 2.8 × 10−8 M); the binding can
be further strengthened by interaction of galectin-9 with glycosylated
Tim-3 (Prokhorov et al., 2015). Indeed, the complex is detectable by
Western blot, which means that interaction between a lectin andsugar is taking place. SRCD spectroscopy was also performed on
galectin-9 and Tim-3 mixed to a stoichiometry of 1:1 molar ratio (Fig.
5B). Galectin-9 when mixed with Tim-3 showed a CD spectrum signiﬁ-
cantly different from the simulated spectrum indicating that the inter-
action of galectin-9 with Tim-3 causes signiﬁcant conformational
change of the proteins with a clear increase in β-strand component.
Based on the above, one might speculate that Tim-3 binding could
alter the conformation of galectin-9, resulting in increased ability to in-
teract with receptors in target cells. Since galectin-9 is a tandem protein
with two sugar binding domains, one domain could bind Tim-3 (or
other proteins) and leave the other domain open for interaction with
a receptor molecule associated with the plasma membrane of a target
cell (for example membrane associated Tim-3).
3.5. Latrophilin 1, Protein Kinase C andmTOR-Dependent Translation Play a
Crucial Role in Tim-3 and Galectin-9 Production and Secretion
LPHN1mRNAwas found in primary humanCD34-positive stem cells
(Maiga et al., 2016).Wewere able to detect LPHN1 protein in them (at a
slightly highermolecular weight than in THP-1 cells (around 140 kDa)),
while in THP-1 it is detectable at 130 kDa (Supplementary Fig. 3) aswell
as in primary AML cells (Sumbayev et al., 2016). No Tim-3 or galectin-9
protein expression was detectable in primary human CD34-positive
stem cells (Supplementary Fig. 3).
For this experimental set-up we used THP-1 cells and exposed
them to 100 nM PMA or 250 pM α-latrotoxin (LTX, a highly speciﬁc
and potent ligand of LPHN1 (Sumbayev et al., 2016)). We found that
both PMA and LTX downregulated intracellular Tim-3 and galectin-9
levels (though not signiﬁcantly) and signiﬁcantly increased activat-
ing phosphorylation of the mammalian target of rapamycin
(mTOR) at S2448 (Fig. 6A and B). One hour pre-treatment of THP-1
cells with 70 nM Gö6983 (PKCα inhibitor) before exposure to PMA
or LTX led to attenuation of stimulus-induced mTOR activation and
downregulation of intracellular Tim-3 and galectin-9 levels.
Interestingly, in the cells exposed just to Gö6983, phospho-S2448
mTOR and intracellular Tim-3/galectin-9 levels were not different
Fig. 5. Interaction of Tim-3with galectin-9 leads to major conformational changes increasing solubility of the protein complex. (A) The schematic structural models of Tim-3 extracellular
domain (left) and galectin-9 (right). In the Tim-3 structure, amino acid residues involved in galectin-9-independent binding are highlighted in green. Residues, which are potential targets
for glycosylation, are highlighted in red. In galectin-9, sugarmolecules,which could potentially bind theprotein, located close to the carbohydrate binding sites are shown in green. (B) The
SRCD spectroscopy of Tim-3, galectin-9 and Tim-3-galectin-9 interaction (both simulated and real curves are presented).
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both sTim-3 and galectin-9 from THP-1 cells. Gö6983 completely
attenuated this increase in both cases, but did not change basic levels
of Tim-3 and galectin-9 secretion, which suggests that basic
(background) release of galectin-9 and Tim-3 does not depend on
PKCα (Fig. 6D).
In summary, both PMA and LTX induce production of both Tim-3
and galectin-9 in THP-1 cells. We conﬁrmed that THP-1 cells express
Gαq (Supplementary Fig. 4A) and PMA aswell as LTX induce highly sig-
niﬁcant upregulation of PKCα kinase activity (Supplementary Fig. 4B).
Pre-treatment of THP-1 cells with 10 μM AZD2014 (a highly speciﬁc
mTOR inhibitor) before exposure to PMA or LTX reduced intracellular
Tim-3 and galectin-9 levels as well as release of both proteins (Fig. 6C
and D). This indicates that PMA or LTX-induced translation of both pro-
teins depends on the mTOR pathway. Importantly, the solvents used toFig. 6. LPHN1, PKCα andmTOR pathways are involved in Tim-3 and galectin-9 production and
LTX for 16 h with or without 1 h pre-treatment with the PKCα inhibitor Gö6983 (A, B, D) or the
Western blot. Released Tim-3 and galectin-9 were detected by ELISA. Images are from one expe
values ± SEM of three independent experiments; *p b 0.05; **p b 0.01; ***p b 0.001 vs. control.
cells, respectively.dissolve pharmacological inhibitors had no effect on any of the studied
protein levels or their secretion (data not shown).
These results were validated using primary human AML cells. For
this purpose we exposed primary human AML mononuclear blasts
AML-PB001F for 24 h to LTX followed by detection of secreted
galectin-9 and Tim-3. We found that AML-PB0011F expressed LPHN1
and the secreted levels of both proteins were signiﬁcantly increased in
LTX-treated AML cells (Supplementary Fig. 5) conﬁrming the ﬁndings
obtained in THP-1 cells.
To conﬁrm the physiological role of LPHN1 in galectin-9 release we
exposed THP-1 cells to FLRT3, which is one of physiological ligands of
LPHN1 (Boucard et al., 2014). We found that 10 nM FLRT3 induced sig-
niﬁcant upregulation of galectin-9 and sTim-3 release (Fig. 7A, a scheme
of the experiment is presented in Supplementary Fig. 6A); it also upreg-
ulated PKCα activity in THP-1 cells (Supplementary Fig. 4B). To conﬁrmsecretion in AML cells. THP-1 cells were exposed to the indicated concentrations of PMA or
mTOR inhibitor AZD2014 (C, D). Cellular levels of Tim-3 and galectin-9 were analyzed by
riment representative of three which gave similar results. Quantitative data are the mean
Symbols “a” or “b” are used instead of “*” to indicate differences vs. PMA and LTX-treated
Fig. 7. FLRT3, a physiological ligand of LPHN1, induces galectin-9 and Tim-3 secretion. (A) THP-1 cells were exposed for 16 h to 10 nM extracellular domain of human recombinant FLRT3
followedbymeasurement of released Tim-3 and galectin-9 by ELISA. (B) THP-1 cellswere exposed tomouse bonemarrow (mBM) extracts for 16 hwith orwithout 1 h pre-treatmentwith
5 μg/ml anti-FLRT3 antibody. The presence of FLRT3 in mBM extracts was conﬁrmed by Western blot analysis. Secreted Tim-3 and galectin-9 were measured by ELISA. (C, left) RCC-FG1
cells express FLRT3 as conﬁrmed byWestern blotting. (C, right) RCC-FG1 cells were co-culturedwith THP-1 cells at a ratio of 1 THP-1:2 RCC-FG1with orwithout 1 h pre-treatmentwith 5
μg/ml FLRT3 neutralizing antibody. Secreted galectin-9 and Tim-3 were measured by ELISA. Images are from one experiment representative of three which gave similar results.
Quantitative data depict mean values ± SEM of three independent experiments; *p b 0.05; **p b 0.01; ***p b 0.001 vs. control. Symbols “a” or “b” are used instead of “*” to indicate
differences vs. cells treated with mBM extracts or co-cultured with RCC-FG1 cells, respectively.
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16 h to mouse bone marrow (mBM) extracts (10 μg protein/ml, which
contain FLRT3, Fig. 7B, a scheme of the experiment is presented in Sup-
plementary Fig. 6B) obtained as outlined in the Materials and Methods.
Treatments were conducted with or without 1 h pre-treatment with 5
μg/ml FLRT3 neutralizingmouse antibody.We found that mBMextracts
signiﬁcantly upregulated galectin-9 and sTim-3 secretion in THP-1 cells.
FLRT3 neutralizingmouse antibody reduced the effects of mBM extracts
but did not block them (Fig. 7B). This means that BM contains several
activators of galectin-9 secretion in AML cells. Finally, we co-cultured
THP-1 cells with RCC-FG1 renal carcinoma cells (which are highly ad-
herent) in the ratio 1 THP-1:2 RCC-FG1. RCC-FG1 cells express high
levels of FLRT3 and release almost undetectable amounts of galectin-9
(Fig. 7C, a scheme of the experiment is presented in SupplementaryFig. 8. LAD2 cells express and externalize Tim-3 and galectin-9. Left panel: surface-based and to
COR in cell assay (ICA, non-permeabilized cells) and in cell Western (ICW, permeabilized cell
sensitized LAD2 cells by Western blot. Galectin-9 release was characterized using ELISA.
Quantitative data show mean values ± SEM of three independent experiments; ***p b 0.001 vFig. 6C). Cells were kept together for 16 h in the absence or presence
of 5 μg/ml FLRT3 neutralizing antibody and then galectin-9 and sTim-
3 secretion levels were analyzed. We found that the presence of RCC-
FG1 cells signiﬁcantly increased galectin-9 and sTim-3 release and
FLRT3 neutralization attenuated these effects. The presence of RCC-
FG1 cells signiﬁcantly upregulated PKCα activity, an effect that was
also attenuated by neutralization of the FLRT3 (Supplementary Fig.
4C). These results suggest that FLRT3 stimulates the release of
galectin-9 from AML cells.
3.6. Galectin-9 and sTim-3 Attenuate AML Cell Killing Activity of NK Cells
Recent evidence suggested that galectin-9 (either soluble or cell sur-
face associated) can interact with Tim-3 or possibly other receptors ontal Tim-3 and galectin-9 were measured in LAD2 humanmast cell sarcoma cells using LI-
s). Right panel: protein levels of Tim-3 and galectin-9 were measured in resting and IgE-
Images are from one experiment representative of three which gave similar results.
s. control.
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(Gleason et al., 2012). Itmay be proposed that Tim-3-galectin-9 interac-
tion is involved in the creation of immunological synapses between tar-
get cells and cytotoxic lymphoid cells. To investigate this we used LAD2
humanmast cell sarcoma cells kindly provided by Prof. Metcalfe andDr.
Kirshenbaum (NAID, NIH, USA; Kirshenbaum et al., 2003). These cells
express both Tim-3 and galectin-9 with both proteins located mostly
on the cell surface (Fig. 8) and not rapidly shed. This can thus be used
to visualize the formation of immunological synapses between the
two cell types. They also express high afﬁnity IgE receptors (FcɛRI)
which are not expressed by NK cells and thus can be used to distinguish
between the two cell types.
Resting LAD2 cells do not release detectable amounts of galectin-9
and sensitization with IgE (which was used in order to label the cells
for visualization) does not augment galectin-9 secretion considerably
(Fig. 8). We therefore immobilized primary human NK cells isolated
frombuffy coats of human blood on ELISA plates as outlined inMaterials
and Methods. NK cells express Tim-3 (several glycosylation variants,
Supplementary Fig. 7) but do not produce detectable amounts of
galectin-9 protein. We applied IgE-sensitized LAD2 cells (Sumbayev et
al., 2012) to the NK cells at a ratio of 1:1 with or without 15 min pre-in-
cubationwith galectin-9 neutralizing antibody. Isotype control antibody
was also used instead of galectin-9 antibody to rule out the IgG effect.
LAD2 cells were then ﬂagged using mouse IgM anti-IgE followed by vi-
sualization using anti-mouse LI-COR secondary antibody (which recog-
nizes IgM, seeMaterials andMethods for further details).We found that
LAD2 cells were binding to NK cells and the presence of galectin-9 neu-
tralizing antibody (but not isotype control antibody) abrogated this ef-
fect (Fig. 9, a scheme of the experiment is presented in Supplementary
Fig. 8). These results conﬁrm that galectin-9 produced by LAD2 cells
participates in their interactions with NK cells. Furthermore, abrogation
of the effect by anti-galectin-9 antibodies may indicate that the Tim-3-
galectin-9 interaction is the only pathway through which these cells
could interact. This is most likely a result of IgE sensitization of LAD2
cells which highly increases the presence of galectin-9 on their surface.
We then used K562 chronic myeloid leukemia cells which do not re-
lease detectable amounts of galectin-9 (as conﬁrmed by ELISA). K562
cells were exposed to PMA for 24 h in 96well Maxisorp plates. Medium
was replaced with PMA-free RPMI-1640 medium containing isolated
primary humanNK cells at a ratio of 1 K562:2 NK in the absence or pres-
ence of 5 ng/ml human recombinant galectin-9. Cells were co-incubated
for 16 h and their viability was then assessed using an MTS test. WeFig. 9.Galectin-9participates in the formation of an “immunological synapse” betweenNK
cells and LAD2cells. Primary humanNK cellswere immobilized on the surface ofMaxisorp
plates. Cells were then co-incubated for 30 min with LAD2 cells with or without 30 min
pre-treatment of LAD2 cells with 5 μg/ml galectin-9 neutralizing antibody (or the same
amount of isotype control antibody). LAD2 cells were then visualized using LI-COR assay
as outlined in Materials and Methods. Images are from one experiment representative of
ﬁve which gave similar results. Quantitative data represent mean values ± SEM of ﬁve
independent experiments; *p b 0.05; **p b 0.01.found that the presence of NK cells signiﬁcantly reduced the viability
of K562 cells however, the presence of galectin-9 attenuated K562 kill-
ing effect (Fig. 10A). Viability of NK cells was not affected in any of the
cases (Fig. 10A). Interestingly, the cytotoxic attack by NK cells also led
to a dramatic change in the behavior of K562 cells, causing theirmassive
aggregation. Usingphase contrastmicroscopy,we determined the effect
of galectin-9 on cell aggregation in individual or combined K562 andNK
cell cultures. In the absence of galectin-9, there was clear evidence of
K562 cells aggregating in the presence of NK cells (Fig. 10B). Galectin-
9, in a dose-dependent manner, decreased the aggregation of K562
cells by NK cells, such that no K562 cell aggregation was detectable in
the presence of 5 ng/ml galectin-9 (Fig. 10C). Galectin-9 itself had no
visible effect on either of the two cell types alone. Thus, galectin-9 clear-
ly protects myeloid leukemia cells from being killed by NK cells.
We then investigated the interactions between AML THP-1 cells and
primary human NK cells. THP-1 cells were exposed to 100 nM PMA for
16 h. The medium was then replaced with PMA-free medium contain-
ing NK cells at a ratio of 2 NK cells:1 THP-1 cells and left for 6 h in the
absence or presence of 5 μg/ml galectin-9-neutralizing antibody. Tim-
3 and galectin-9 were then measured in the NK cells by Western blot
analysis, and viability of THP-1 cells, activities of granzyme B, caspase-
3 and galectin-9 release were monitored. We found that THP-1 cell via-
bility was reduced when galectin-9 was neutralized (Fig. 11). This was
in line with increased caspase-3 activity and granzyme B activities.
Galectin-9 releasewas not affected (Fig. 11, galectin-9 bound to neutral-
izing antibody is detectable in our system). We conﬁrmed that resting
NK cells did not produce detectable amounts of galectin-9. However,
this protein on its own, and in the form of unbroken Tim-3-galectin-9
complex, was detectable in NK cells co-cultured with THP-1 cells and
was reduced in the presence of galectin-9 neutralizing antibody. This
suggests that THP-1 cells were the source of galectin-9, which was
most likely bound to Tim-3 on the surface of NK cells, preventing the de-
livery of NK cell-derived granzyme B into THP-1 cells and inhibiting the
caspase-3-dependent apoptotic pathway.
Recently, a possible reciprocal link between levels of sTim-3 and IL-
2, a cytokine, which activates cytotoxic activity of NK cells and T cells,
was reported (Geng et al., 2006). We also found that in the plasma of
healthy donors the levels of sTim-3 were signiﬁcantly lower compared
to AML patients (Fig. 4) whereas the levels of IL-2 were signiﬁcantly
higher (Fig. 12A and B). To investigate a possible direct inﬂuence of
sTim-3, we exposed Jurkat T cells (resting Jurkat T cells produce detect-
able amounts of IL-2) to increasing concentrations of Tim-3 for 24 h.We
found a striking sTim-3 concentration-dependent and signiﬁcant reduc-
tion of IL-2 release from Jurkat T cells. This indicates that sTim-3 is capa-
ble of binding a target protein (or a group of target proteins) and
reducing IL-2 production thus preventing induction of NK cell and T
lymphocyte anti-cancer activities.
Taken together, our results demonstrate a pathobiochemical path-
way in AML cells. It is associated with activation of PKCα by LPHN1
(or any other receptors with similar activity) leading to the expression
and exocytosis of sTim-3 and galectin-9, which prevent the activation
of cytotoxic lymphocytes and impair their malignant cell killing activity.
4. Discussion
AML is a malignancy affecting bone marrow and blood and is a se-
vere, and often fatal, systemic disease. AML cells escape host immune
attack involving NK and cytotoxic T cells by impairing their activity
(Golden-Mason et al., 2013; Kikushige et al., 2015; Gonçalves Silva et
al., 2016). However, the biochemical mechanisms underlying the im-
mune escape of malignant white blood cells remain unclear. Recently,
it was shown that AML cells express high levels of the immune receptor
Tim-3 and release galectin-9 which impairs the activity of NK cells and
cytotoxic T cells (Gonçalves Silva et al., 2016). We have also suggested
that Tim-3, as a membrane associated glycoprotein, might act as a traf-
ﬁcker for galectin-9 (Gonçalves Silva et al., 2016). As for all galectins,
Fig. 10.Galectin-9 protectsmyeloid leukemia K562 cells frombeing killed by primary humanNK cells. (A) K562 cellswere co-cultured for 16 hwith primary humanNK cells (at a ratio of 1
K562:2 NK) in the absence or presence of 5 ng/ml galectin-9. Viability of K562 and NK cells was thenmeasured using anMTS test. Images are from one experiment representative of three
which gave similar results. Quantitative data represent mean values ± SEM of three independent experiments; ***p b 0.001 vs. control. (B) K562 cells were co-cultured for 16 h with
primary human NK cells (at a K562:NK ratio of 1:2) in the presence of different concentrations of galectin-9 (0–5 ng/ml). Cells were imaged using phase-contrast microscopy. The
images are from one representative experiment of six (n= 6), which gave similar results. Scale bar (the same for all images), 50 μm. (C) The NK cell-induced aggregation of K562 cells
was quantiﬁed as a function of galectin-9 concentration. Left panel: percent of cells found in aggregates in individual cultures and in co-culture. Right panel: the size of cell aggregates
in individual cultures and in co-culture. The data represent the mean values ± SD of six independent experiments; *, p b 0.05; **, p b 0.01; ****, p b 0.0001.
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domain required for secretion it thus needs a trafﬁcker in order to be re-
leased (Delacour et al., 2009). When on the cell surface, Tim-3 is known
to be shed by ADAM 10/17 proteolytic enzymes thus producing sTim-3,
the function of which remains unknown (Moller-Hackbarth et al.,
2013). We found, that Tim-3 could be shed in its free form as well as
in complex with galectin-9; however, differential shedding is taking
place. The Tim-3 fragment in the complex is about 20 kDa molecular
weight, while sTim-3 is around 33 kDa. SRCD analysis of the complex
suggests that the interaction between Tim-3 and galectin-9 proteins
leads to major conformational change, possibly increasing the abilityof galectin-9 to interact with the target proteins. Since galectin-9 is a
tandem protein containing two domains (Delacour et al., 2009), one of
them might be interacting with Tim-3, while the other one could bind
to a target receptor molecule, for example another molecule of Tim-3
associated with the plasma membrane of the target cell (Nagae et al.,
2006). This may explain the high efﬁciency of galectin-9 in triggering
Tim-3 onNK cells, which do not express galectin-9 and thus contain un-
occupied Tim-3 on their surface.
Since we can observe the Tim-3-galectin-9 complex on Western
blots following denaturing SDS-gel electrophoresis (Figs. 1, 2 and 4;
~52 kDa soluble form and ~70 kDa cell-derived form), it is likely that
Fig. 11. Cell-derived galectin-9 attenuates AML cell killing activity of primary human NK cells. THP-1 cells were co-incubated with primary human NK cells (ratio – 1 THP-1:2 NK) for 6 h
followed by detection of THP-1 cell viability by the MTS test, measurement of activities of granzyme B and caspase 3 in THP-1 cell lysates and released galectin-9 (left panel). Galectin-9
levels from NK cells were determined by Western blot (right panel). Images are from one experiment representative of three which gave similar results. Quantitative data show mean
values ± SEM of three independent experiments; *p b 0.05; **p b 0.01; ***p b 0.001 vs control.
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of galectin-9 with Tim-3-associated glycosides. Interestingly, the com-
plex is detectable by Western blot with both anti-Tim-3 and anti-
galectin-9 antibodies. However, when these antibodies are sequentially
applied to the same blot, the second antibody fails to detect the respec-
tive protein in the same band (unless the ﬁrst antibody is stripped off),
due to steric hindrance. This effect explains why Tim-3 located on theFig. 12. Soluble Tim-3 attenuates IL-2 release. (A and B) IL-2 levels were measured by ELISA in
increasing concentrations of Tim-3 for 24 h followed by detection of secreted IL-2 by ELISA. Dacell surface and covered by galectin-9 cannot be co-stained by the anti-
body in confocal microscopy co-localization analysis (Fig. 3). Another
point supporting this conclusion is that there was also clear evidence
of co-localization of Tim-3 and galectin-9 in permiabilized THP-1 cells
upon exposure to PMA (Fig. 3, Supplementary Fig. 1).
Previously it was reported that the release of both Tim-3 and
galectin-9 depends on PKCα and proteolysis (Chabot et al., 2002). Ourblood serum of healthy donors and AML patients. (C) Jurkat T cells were exposed to the
ta show mean values ± SEM of three independent experiments; *p b 0.05; **p b 0.01.
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tion, which activated exocytosis of Tim-3 and galectin-9 as well as their
mTOR-dependent production in THP-1 AML cells (Fig. 6).
Interestingly, natural and exogenous ligands of LPHN1, a G-protein
coupled neuronal receptor expressed also in CD34-positive human
stem cells (Supplementary Fig. 3) and AML cells but not healthy white
blood cells, activated the PKCα pathway. They also induced both
mTOR-dependent translation of Tim-3 and galectin-9 as well as their
exocytosis. The effect was observed in THP-1 and primary human AML
blasts. PKCα is known to provoke agglomeration of SNARE complex re-
sponsible for exocytosis (Stockli et al., 2011; Morgan et al., 2005). Since
FLRT3, one of natural ligands of LPHN1, is present in bone marrow (Fig.
7) it might explain how LPHN1 causes PKCα activation. Interestingly,
constitutively active PKCα in malignant primary AML cells correlates
with a very poor prognosis and high mortality rate of patients
(Kurinna et al., 2006). This suggests that AML cells constantly release
high levels of Tim-3 and galectin-9. Bone marrow also expresses other
PKCα-activating proteins. When we exposed THP-1 cells to mouse
bone marrow extracts, galectin-9 release was signiﬁcantly higherFig. 13.AML cell-based pathobiochemical pathway showing LPHN1-induced classic activation of
required for immune escape. The interaction of FLRT3 located on the surface of endothelial cells
Ligand-bound LPHN1 activates Gq, which in then stimulates PLC. This leads to phosphatidyl-in
diacylglycerol (DAG). IP3 interacts with ER-associated IP3 receptor (IP3R) leading to Ca2+ m
through downregulation of TSC1/TSC2. mTOR controls translation of Tim-3 and galectin-9. PK
of SNARE complexes that tether vesicles to the plasma membrane. This pre-activates the re
complexed Tim-3. Both types of Tim-3 are differentially shed from the cell surface by proteoly
cytotoxic T cells. Galectin-9 impairs AML cell killing activity of NK cells (and other cytotoxic lycompared to resting THP-1 cells. FLRT3 neutralizing antibody signiﬁ-
cantly reduced but did not abolish FLRT3 induced PKCα-dependent
galectin-9 release. This suggests that galectin-9 and Tim-3 are synthe-
sized and exocytozed by AML cells in a PKCα and mTOR-dependent
manner, using available plasma membrane-associated PKCα activating
receptors (for example LPHN1) to induce the whole pathway.
Galectin-9 prevents thedelivery of granzymeB into AML cells (this is
a perforin and mannose-6-phosphate receptor-dependent process
(Supplementary Fig. 9)). Inside AML cells granzyme B performs cleav-
age of the protein Bid into tBid, thus inducing mitochondrial dysfunc-
tion and cytochrome C release followed by caspase 3 activation.
Proteolytic activation of caspase 3, in addition to the classic pathway,
might also be directly catalyzed by granzyme B (Lee et al., 2014). Our re-
sults with galectin-9 conﬁrmed this concept (Fig. 11). Recently it was
reported that galectin-9 induces interferon-gamma (IFN-γ) release
from NK cells (Gleason et al., 2012). IFN-γ interacts with AML cells in-
ducing the activity of indoleamine 2,3-dioxygenase (IDO1), an enzyme
which converts L-tryptophan into formyl-L-kynurenine, which is then
converted into L-kynurenine and released (Corm et al., 2009; FolgieroPKCα, which triggers translation of Tim-3 and galectin-9 aswell as their secretionwhich is
(EC)with LPHN1 leads to the activation of PKCα through the classic Gq/PLC/Ca2+ pathway.
ositol-bisphosphate (PIP2) degradation and production of inositol-trisphospate (IP3) and
obilization. PKCα is activated by DAG and Ca2+ activates mTOR translational pathway
Cα also phosphorylates Munc18 exocytosis regulator protein which provokes formation
lease machinery, and elevated cytosolic Ca2+ lead to exocytosis of free and galectin-9-
tic enzymes. Soluble Tim-3 prevents IL-2 secretion required for activation of NK cells and
mphocytes).
56 I. Gonçalves Silva et al. / EBioMedicine 22 (2017) 44–57et al., 2015; Mabuchi et al., 2016). L-kynurenine affects the ability of NK
cells to kill AML cells, an effect which was seen in our experiments and
presented in Supplementary Fig. 9. Soluble Tim-3 was shown to
signiﬁcantly downregulate production of IL-2, a cytokine required for
activation of NK cells and cytotoxic T lymphocytes.
Taken together, our results show that human AML cells possess a se-
cretory pathway which leads to the production and release of sTim-3
and galectin-9. Both proteins prevent the activation of NK cells and im-
pair their AML cell-killing activity. This pathway, which involves the
LPHN1-dependent activation of Tim-3 and galectin-9 production is
summarized in Fig. 13. The described pathway presents both bio-
markers for AML diagnostics and potential targets (both sTim-3 and
galectin-9) for AML immune therapy and thus can be considered as a
fundamental discovery.
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